AU Patent

AU2002350750B2 — Compressed oral pharmaceutical dosage form, with an enteric coating, which contains an acid-labile benzimidazole compound

Assigned to Esteve Pharmaceuticals SA · Expires 2008-10-16 · 18y expired

What this patent protects

The pharmaceutical dosage form consists of a plurality of units containing a benzimidazole compound labile in an acid medium as the active principle, each unit being comprising an inert core, a layer containing the active principle and an intermediate layer. These units, mixed wi…

USPTO Abstract

The pharmaceutical dosage form consists of a plurality of units containing a benzimidazole compound labile in an acid medium as the active principle, each unit being comprising an inert core, a layer containing the active principle and an intermediate layer. These units, mixed with compression excipients, compressed and coated with an enteric coating, provide a tableted pharmaceutical dosage form suitable for oral administration for preventing and treating disorders related to an abnormal secretion of gastric acid.

Drugs covered by this patent

Patent Metadata

Patent number
AU2002350750B2
Jurisdiction
AU
Classification
—
Expires
2008-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Esteve Pharmaceuticals SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.